End-stage liver disease includes liver failure and decompensated cirrhosis resulting from various etiologies and often leads to patient mortality due to complications and clinical symptoms such as severe jaundice, ascites, hepatic encephalopathy, coagulopathy, and hepatorenal syndrome. Liver transplantation is currently regarded as the most effective treatment, but its clinical application is limited by the shortage of donors, elevated expenses, and post-transplant rejection. Stem cells are a group of cells with multidirectional differentiation potential and self-renewal ability, which can improve the clinical indicator outcomes through mechanisms such as immunoregulation and promotion of tissue repair in patients with end-stage liver disease. Clinical trials of stem cell therapy have achieved a series of results for end-stage liver disease, proving the safety and effectiveness of stem cell therapy. This article reviews the clinical studies that have been registered and published at home and abroad and provides a reference for the clinical plan on stem cell therapy for end-stage liver disease.
终末期肝病包括各种原因导致的肝衰竭和失代偿期肝硬化，常因并发重度黄疸、腹水、肝性脑病、凝血功能障碍、肝肾综合征等临床症状导致患者死亡。目前肝移植被视为最有效的治疗方法，但由于供体匮乏、成本高昂及移植后的排斥反应等原因限制了其临床应用。干细胞是一群具有多向分化潜能、自我更新能力的细胞，可通过免疫调节、促进组织修复等功能改善终末期肝病患者的临床指标。干细胞治疗终末期肝病的临床试验已取得一系列成果，证明了干细胞治疗该类疾病的安全性和有效性。该文对目前国内外已注册和发表的干细胞治疗终末期肝病的临床研究进行了综述，为干细胞治疗终末期肝病的临床方案提供参考。.